TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan, representing a year-on-year increase of 3.7%. Other income and gains reached 37.609 million yuan, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily consisted of government grants related to revenue, interest-free financing subsidies, and gains from the sale of a subsidiary. As a company focused on developing small-molecule targeted therapies for cancer treatment, TYK MEDICINES-B has established a pipeline comprising ten drug candidates. Building upon its existing organizational structure, the company is progressively expanding its commercial team to explore market potential. It continues to deepen the sales potential of its products and enhance brand promotion through participation in various academic conferences, industry collaborations, and platform partnerships, thereby diversifying its corporate branding initiatives and increasing its visibility within the sector.